EFPIA’s vision for the future of cancer treatment in Europe beyond 2025

The convergence of cutting-edge technologies and breakthroughs in the scientific understanding of cancer have enabled unprecedented opportunities for precision oncology (PO), according to a posting on the European Federation of Pharmaceutical Industries and Associations (EFPIA).

At the core of PO is the ability to identify optimal treatments tailored to each patient’s unique biological characteristics, breaking away from conventional one-size-fits-all approaches centered around tumor location.

This revolutionary approach brings significant advantages for both individual patients and healthcare systems. Patients experience improved response rates, elevated survival rates, and enhanced long-term outcomes, minimizing unnecessary side effects and complications. For healthcare systems, PO offers an avenue to reduce costs and alleviate the strain on an already burdened healthcare workforce.